The University of Southampton
University of Southampton Institutional Repository

Shortened peginterferon and ribavirin treatment for chronic hepatitis C

Hartwell, Debbie, Jones, Jeremy, Baxter, Louise and Shepherd, Jonathan (2012) Shortened peginterferon and ribavirin treatment for chronic hepatitis C International Journal of Technology Assessment in Health Care, 28, (4), pp. 1-9. (doi:10.1017/S0266462312000463).

Record type: Article


Background: Peginterferon alfa and ribavirin combination therapy is an effective treatment for many patients with chronic hepatitis C virus (HCV). Reducing the length of treatment may be advantageous. We performed a systematic review and economic evaluation to assess shorter treatment duration of this regimen.
Methods: We searched fourteen bibliographic databases (including The Cochrane Library, Medline, and Embase) from 2000 to October 2009 and consulted experts and drug manufacturers. Eligible articles were randomized controlled trials (RCTs) selected according to predefined criteria. We undertook an economic evaluation to assess the cost-effectiveness of shortened treatment versus standard treatment in the UK.
Results: Six trials were included. In the sub-group of patients who had low viral load (LVL) and a rapid virological response (RVR), there were no statistically significant differences in sustained virological response (SVR) rates between patients who received standard treatment (range, 83 percent to 100 percent) and those who received shortened courses (range 84 percent to 96 percent)
(24 weeks for genotype 1, 16 weeks for genotype 2/3). Shortened treatment resulted in cost savings, but in some scenarios also resulted in poorer outcome, compared with standard treatment. This requires a judgment to be made on the value of the quality-adjusted life-year loss resulting from adopting a shorter treatment regimen, if shorter treatment is associated with a lower SVR than standard treatment duration.
Conclusions: For chronic HCV patients who have LVL and achieve an RVR, shortened peginterferon and ribavirin combination therapy could be considered as a viable treatment option.

Full text not available from this repository.

More information

Published date: 2012
Organisations: Clinical & Experimental Sciences


Local EPrints ID: 343412
ISSN: 0266-4623
PURE UUID: 86d8096b-502e-4f91-9f95-1f4402de7e4a

Catalogue record

Date deposited: 04 Oct 2012 14:43
Last modified: 18 Jul 2017 05:22

Export record



Author: Debbie Hartwell
Author: Jeremy Jones
Author: Louise Baxter

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.